This is a Phase III open-label study to assess if Camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician.
For More Information
If you are interested in this clinical trial, please email the Cancer Care Northwest Research Department at research@ccnw.net for more information. Be sure to include:
